- ABOUT FORZA
- THE REVIEWS
- THE STORY
- INDEPENDENT R&D
- THE SOURCE
- THE PLAN
- THE PRODUCTION
- ABOUT US
- CONTACT US
The Osmotin plant protein was discovered in 1987, and it has since been universally recognized for the important protective role it plays in plants' response to environmental stresses. It was also established, however, that, although Osmotin is present in all plants, it is only found in minimal amounts.
Following this discovery, biotech laboratories in universities around the world launched various research projects to better understand and harness Osmotin's potential in plants.
One such lab in a leading agricultural Italian University focused on the daunting task of bionegineering Osmotin-rich olive trees and kiwi vines, as these plants are among Italy's principal exports, with major economic, environmental, and cultural values. The research effort was led by our Chief Biotechnology Advisor Prof. Eddo Rugini, Ph.D. and our CEO Dr. Bruno Ruggiero, PhD.
Not only was the Italian team successful in the lab, but following about 10 years of R&D, the now Osmotin overexpressing plants were also successfully field-tested for another 10 years, confirming their ability to thrive under drought-stress, cold stress, fungal attacks and overall having superior agronomic qualities compared to common kiwi and olive varieties.
Meanwhile, in 1995, in a seemingly unrelated event, the human hormone Adiponectin was discovered in the adipose tissue, which gives it its name. It quickly became clear that Adiponectin could be an excellent anti-diabetes therapeutic target candidate. However, as time went by, no practical way of using Adiponectin therapeutically was identified. Efforts to create a synthetic version of Adiponectin failed as well.
In the late 1990s, following his success with the development of the Osmotin-rich olive and kiwi plants in Italy, our CEO Dr. Bruno Ruggiero, Ph.D. was invited to continue his work on Osmotin by joining a US-based team of plant biotech researchers at Purdue University, one of the world's leading agricultural universities. The US-based team set to work, and they soon noted a remarkable similarity between the newly published 3D structure of Adiponectin and that of the plant protein Osmotin. If they were right, this overlapping of structures meant that Osmotin would mimic Adiponectin's therapeutic activity and, as it was sourced from plants, theoretically, Osmotin could become a tangible and powerful anti-diabetes therapeutic candidate. The initial laboratory work in animal diabetes models confirmed this expectation and a entirely new horizon of opportunities became open to exploration.
Osmotin's and Adiponectin's 3D structures overlap allowing Osmotin to mimic Adiponectin's functions.
In January 2005, the US Embassy in Japan made an official announcement celebrating this discovery and praising its significance in the fight against diabetes, obesity, and heart disease.
Dr. Ruggiero, who had by then completed his PhD., had also founded his first biotech company in the US and launched it on the London Stock Exchange, and continued his work on Osmotin, among other cutting edge biotechnologies. In 2004 Bruno provided a $1 million USD gift to Purdue University to promote research on Osmotin's human health applications.
In the nearly three decades of research performed since Adiponectin's discovery, the understanding of its role has far surpassed its initial qualification as a anti-diabetic. Indeed, its receptors are now known to be expressed in all 11 organ systems of the human body and Adiponectin is now seen as a key life-span and health-span regulator.
This was the pivotal moment when the earlier work of the development of the Osmotin-rich kiwi and olive plants had now taken on a new importance as these plants would represent the ideal source of industrial amounts of Osmotin, which could finally be used practically in place of Adiponectin.
With this in mind, in 2013 Dr. Ruggiero co-founded 9th Dimension Biotech, Inc. with the goal of bringing a life-time of experience in biotech and the best technology in the field to the market with a strategic and solution-oriented approach. As a company we have developed an eclectic portfolio of technologies, including our most advanced, market-ready tech represented by our Osmotin kiwi and olive plants. Indeed we have secured exclusive global commercial rights over these plants and all of their derivates and have completed testing and development of our first Osmotin-rich product FORZA™️.
FORZA™️ is a nutraceutical supplement, produced by simply harvesting the leaves of our Osmotin-rich kiwi plants, lyophilising them, grinding and encapsulating them. Every cell in our plants is like a tiny factory producing large amounts of Osmotin and allowing the final production process of FORZA™️ to be greatly simplified. The Food and Drug Administration (FDA) has identified this method of protein production as the absolute best due to the plant cells' ability to protect the proteins from being broken down in the digestive tract and only releasing them in the gut for a more powerful and beneficial therapeutic effect.
We conducted over 4 years of market testing of our plants and the results have surpassed the best expectations we could have had based on the decades of independent published research, so much so that we have now launched a phase 2 clinical trial in Progressive Multiple Sclerosis in partnership with the Italian National Multiple Sclerosis Foundation and the General Hospital of San Martino, in Genoa, Italy. Results are expected in 2024.
Dr. Ruggiero has remained a leading expert on both Adiponectin and Osmotin. In 2016 he was honored to receive a US Einstein visa for his work in this field, while remaining faithful to his entrepreneurial and pioneering spirit. At 9th Dimension Biotech, he has developed a powerful interdisciplinary network of relationships and collaborations with the world's leading scientists and best research institutions in pursuit of his mission to identify and develop the most promising technologies to offer quality solutions to the world's most difficult problems.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
Copyright © 2022
9th Dimension Biotech, Inc.
All Rights Reserved.
By accepting, you agree that your data will be aggregated with the data of all other users.